Although STEAP1 CAR-T has not yet been applied in the clinical trial setting, it showed promising anti-tumor activity in prostate cancer with CAR-T cell expansion and infiltration into the tumor microenvironment both in vivo and in vitro (7). Here, STEAP1 is linked to neoplasm.